Skip to main content
. 2019 Dec 31;9(1):102. doi: 10.3390/jcm9010102

Figure 2.

Figure 2

Kaplan–Meier survival curves of progression-free survival (PFS) and overall survival (OS) of patients who received immune checkpoint inhibitor (ICI) rechallenge treatment. (a) PFS of non-small cell lung cancer (NSCLC) patients (n = 35) on first ICI treatment. (b) OS of NSCLC patients (n = 35) on first ICI treatment. (c) PFS of NSCLC patients (n = 35) on ICI rechallenge treatment. (d) OS of NSCLC patients (n = 35) on ICI rechallenge treatment.